Video
Dr. Schweizer on olaparib plus bipolar androgen therapy in mCRPC
Author(s):
Video Player is loading.
In this video, Michael Schweizer, MD, discusses the background, findings, and takeaways of the study, “Bipolar androgen therapy (BAT) plus Olaparib in men with metastatic castration-resistant prostate cancer (mCRPC),” presented recently at the 2021 European Society for Medical Oncology Annual Meeting. Schweizer is an associate professor in the division of medical oncology at the University of Washington and an associate professor in the clinical research division at the Fred Hutchinson Cancer Research Center, Seattle, Washington
Related Videos
Shreyas Joshi, MD, recaps AUA session on chemotherapy vs novel NMIBC options
Shay Rajavel, MS3, on CO2 gas embolism during single-port partial nephrectomy
Kevin Zorn, MD, on preserving ejaculation with BPH therapies
Neal Shore, MD, on sasanlimab plus BCG for BCG-naïve NMIBC
Alexander Glaser, MD, on real-world outcomes with Aquablation
Vitaly Margulis, MD, on preliminary safety, efficacy of padeliporfin VTP for UTUC
Joseph Jacob, MD, on the durability of TAR-200 in NMIBC
Margaret Knoedler, MD, on Ho:YAG vs thulium fiber laser for ureteroscopy
John Gore, MD, on radical cystectomy vs bladder-sparing therapy for NMIBC
Jason Hafron, MD, outlines AUA 2025 session on clinical trial recruitment
Related Content
